Dehydroabietamine (DHAA) has a wide range of applications and the pharmaceutical field is its emerging demand end.

Dehydroabietylamine (DHAA), also known as dehydroabietylamine, is an important modified product of rosin and refers to an amine with optical activity. Dehydroabietamine appears as colorless or slightly yellow solid crystal, soluble in dichloroethane, petroleum ether, diethyl ether, acetone, ethanol and other organic solvents, but insoluble in water. Dehydroabietamine has the advantages of good chemical stability, weak alkalinity, and good biological activity. It is widely used in the fields of medicine, dyes, pesticides, metal ion flotation, and anticorrosion.

Rosin is the main raw material of dehydroabidamine. According to statistics from the China Forest Products Industry Association, the production of rosin in my country’s six major production areas from January to October 2021 reached 202,000 tons, a year-on-year increase of 19%. Benefiting from the growth of market demand and the improvement of technological maturity, my country’s rosin production continues to increase, which lays a good foundation for the development of the dehydroabietamine industry.

Dehydroabietamine has a wide range of applications, including medicine, dyes, pesticides, metal ion flotation, anti-corrosion, etc., fungicides, insecticides, optical resolving agents, coating additives, metal corrosion inhibitors, surfactants, antistatic agents, crude oil demulsifiers, etc. as its end products. It is expected that in the future, with the deepening of research, the application scope of dehydroabietamine will be further expanded.

According to the “2023-2028 China Dehydroabietamine (DHAA) Industry Market In-depth Research and Development Prospects Forecast Report》shows that the pharmaceutical field is an emerging demand side for dehydroabietamine, with anti-tumor drugs and anti-cancer drugs as its end products. my country is a country with a large population and a large number of cancer patients. According to statistics from the World Health Organization’s International Agency for Research on Cancer (IARC), there were 19.29 million new cancer cases worldwide in 2020, of which 4.57 million were new cancer cases in my country. Attracted by the market prospects, many pharmaceutical companies and scientific research institutions in my country have laid out the production and research and development track of medicinal dehydroabietamine, further boosting the prosperity of the industry.

There are many participants in my country’s dehydroabietamine market. The main suppliers include Hubei Rishengchang New Materials Technology Co., Ltd., Hubei Jusheng Technology Co., Ltd., Hubei Hengjingrui Chemical Co., Ltd., Shanghai Mairui Biochemical Technology Co., Ltd., and Zibo Qixiang. Tengda Chemical Co., Ltd., Hangzhou Wanjing New Materials Co., Ltd., etc. In recent years, benefiting from the growth in downstream demand, my country’s dehydroabietamine industry has gradually developed in the direction of high performance. It is expected that companies with large-scale production capabilities of high-purity dehydroabietamine will occupy a larger space in the Chinese market in the future.

           Industry analysts said that dehydroabietamine has excellent performance and has broad application prospects in many fields. Benefiting from the continuous in-depth research, the scope of application of dehydroabietamine in my country has continued to expand, and the demand in the pharmaceutical field has further increased. In the future, as local enterprises improve their independent research and development capabilities, the development speed of my country’s dehydroabietamine industry will continue to accelerate, and its market space will further expand.